Medication nonadherence leads to billion dollar losses for pharmaceutical companies, a report indicates.
Nonadherence to medication for chronic conditions results in an estimated $188 billion revenue loss per year for the pharmaceutical industry, according to a report
produced by Capgemini Consulting and HealthPrize Technologies. The loss amounts to 59% of total pharmaceutical revenue in the United States and can be extrapolated to an estimated loss of $564 billion in global pharmaceutical revenues.
The report authors based their findings on adherence data in published medical studies from 2003 to 2012 that included refill data from pharmacy claims. They did not focus on medication for non-chronic conditions, due to lack of adherence data on non-chronic conditions. In addition, most studies did not account for refills beyond the first refill, despite a propensity for reductions in adherence after 3 months of therapy and nonadherence to long-term or lifelong therapy.
Medication classes with the greatest revenue loss due to nonadherence were respiratory agents, antidepressants, anti-ulcerants, antidiabetics, and antipsychotics, according to the report.
In a survey of pharmaceutical executives conducted prior to the report, all respondents said the industry bears some responsibility for improving adherence. In addition, 80% of respondents rated medication adherence as a high priority or the highest priority for their company.
“I believe the pharma industry, health care professionals, and payers all bear an equal responsibility for promoting improved adherence to medication,” said a respondent quoted in the report.
“It is the biggest issue affecting positive treatment outcomes for most chronic therapies,” another respondent is quoted as saying.
The report authors noted that pharmaceutical companies’ existing strategies—including medication adherence teams that recommend traditional or isolated strategies—do not address the problem of nonadherence at its roots and are often inadequate for addressing the problem.
The pharmacist’s position as a frequently visited and trusted health professional offers a unique opportunity for adherence management, Pharmacy Times
Editor-in-Chief Fred Eckel has noted
In addition, several studies have demonstrated the value of pharmacist counseling in both medication initiation and adherence. A study
published in the March 15, 2012, edition of the American Journal of Health-System Pharmacy
found that patients diagnosed with osteoporosis were more likely to initiate therapy after a pharmacist consult. Meanwhile, a program in which pharmacists monitored and counseled hypertension patients
led to better blood pressure control compared with usual care, according to a study presented at the American Heart Association’s Quality of Care and Outcomes Research Scientific Sessions 2012.